Comparative Efficacy of Lekhan Basti with Ushkadi Gana versus Triphala Gana as against Standard Control in Dyslipidaemia (Medoroga): A Research Protocol for a Randomised Controlled Trial

Introduction: Ayurveda addresses Medoroga using a holistic approach, focusing on correcting imbalances and utilising cleansing therapies like medicated enema (Basti). Ushakadi Gana includes herbs with potential lipid-lowering and metabolic effects, but it faces challenges in accessibility and cost. Triphala Gana offers a more accessible herbal alternative. This study aims to compare the efficacy of both formulations, providing insights into their application for managing dyslipidaemia (Medoroga). Need of the study: In modern medicine, Atorvastatin is the drug of choice for treating dyslipidaemia (Medoroga). Dyslipidaemia can be correlated with Medoroga in Ayurveda. The ingredients of Ushakadi Gana are not easily available for the preparation of Basti and do not include herbal drugs. The Ushakadi Gana Basti is effective, it poses challenges due to its high cost, limited accessibility, and concerns regarding its mineral content, which is contraindicated for patients with renal and hepatic impairments. Lekhan Basti with Triphala Gana offers an alternative due to its herbal composition. Aim: To evaluate the efficacy of Lekhan Basti with Ushadi Gana versus Lekhan Basti with Triphala Gana compared to standard control in managing dyslipidaemia (Medoroga). Materials and Methods: A randomised single (assessor) blind triple-arm superiority controlled trial will be conducted at Mahatma Gandhi Ayurvedic College, Hospital and Research Centre, Salod, Wardha, Maharashtra, India, from January 2025 to March 2026. A total of 129 patients will be divided into three groups, each comprising 43 patients. Group A (n=43): Lekhan Basti with Triphala Gana for 16 days, Group B (n=43): Lekhan Basti with Ushakadi Gana for 16 days and Group C (n=43): Standard treatment with Atorvastatin (1 tablet, 10 mg) daily after food for 48 days. Therapeutic outcomes, lipid profile levels, Body Mass Index (BMI), and weight will be assessed at baseline and follow-up. Analysis of Variance (ANOVA) tests will be applied for statistical analysis, with p-value <0.05 considered significant.